Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.

Epstein-Barr virus and Kaposi's sarcoma herpesvirus can activate and lead to the growth of cancerous cells.

Top news of the day from across the health care landscape.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018 thus far.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, provides insight into the future of Any Willing Provider laws for the pharmacy industry.

Both actions follow similar recalls of valsartan-containing products by other manufacturers.

Amazon’s entry into the pharmacy space could be the start of significant changes in the specialty space.

Top news of the day from across the health care landscape.

Fostemsavir (ViiV Healthcare) may be a potential new option for patients with HIV who have become resistant to other medications.

Top news of the day from across the health care landscape.

A new study indicates that there are age-associated gender differences seen in the disease burden of chronic obstructive pulmonary disorder (COPD), with younger women more severely affected.

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion.

Top news of the day from across the health care landscape.

Myriad reasons may prevent patients from accessing specialty drugs, which create significant problems for patients in need of treatment.

Antiretroviral drug treatment was not found to be a cause of the higher prevalence of hypertension in persons infected with HIV.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses how pharmacokinetics has helped patients with hemophilia better manage their disease.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

Tailoring hepatitis C treatments to shorten regimen length can reduce costs and ease burden for patients with limited insurance benefits.

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.

With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.

Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.

Mike Agostino, RPh, President of the National Association of Specialty Pharmacy (NASP), discusses the specialty pharmacist's role in taking a value-based approach to patient care.